PLA2G7 Protein

Catalog No. ABIN7849665

Recombinant PLA2G7 protein expressed in Escherichia coli (E. coli).

Quick Overview for PLA2G7 Protein (ABIN7849665)

Target: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Protein Type: Recombinant

Origin: Human

Source: Escherichia coli (E. coli)

Application: ELISA

Purity: >90 % by SDS-PAGE

Product Details

Purpose: Recombinant Human Lipoprotein-associated phospholipase A2, Lp-PLA2 Protein

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 10 mM Tris-Hcl, pH 10.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Ship at 4°C. Upon receipt, aliquot and store at -20°C or -80°C for long term. Avoid repeated freeze and thaw cycles.

Target Details

Target: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Alternative Name: Lp-PLA2

Background:

Synonyms: PLA2G7, LDL-PLA2, LP-PLA2, PAFAD, PAFAH, PAF-AH, Lipoprotein-associated phospholipase A2, phospholipase A2 group VII, gVIIA-PLA2, PAF acetylhydrolase

Description: Recombinant human LpPLA2 protein with his tag with molecular weight of 65.6 kDa.

Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme that in humans is encoded by the PLA2G7 gene. Both LpPLA2 mass and activity were found within low-density lipoprotein (LDL) and HDL pools with more LpPLA2 mass being associated with HDL (54 % vs 44 %, P-value <.001) and more LpPLA2 activity being associated with LDL (56 % vs 40 %, P value = .02). In T1D, more LpPLA2 activity was associated with large- or less-dense LDL compared to those without diabetes. However, no difference in LpPLA2 activity or mass between lipoprotein subfractions was observed between all groups, and there was no relationship between LpPLA2 activity or mass and its distribution and CAC score progression in healthy or T1D men.LpPLA2 is found in both LDL and HDL and is distributed differently in men with T1D without any relationship to CAC score progression.

Pathways: Peptide Hormone Metabolism